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Abstract: Screening for aneuploidies in the first and second trimester of pregnancy is an important aspect of prenatal 
testing. The overall prevalence of aneuploidy is around 1 in 228 (0.4%). First trimester screening has proved effective in 
identifying aneuploid fetuses, the definitive diagnostic test for aneuploidy available in first trimester is chorion villous 
sampling (CVS).  
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INTRODUCTION 
In the last few decades, the fetus has been 
considered as an individual with extensive efforts in 
investigation and treatment of the unborn. Advances in 
technology and skills in the field of Fetal Medicine has 
enabled us to visualise and manipulate the fetus for 
various prenatal diagnostic procedures and invasive 
fetal therapies.  
Screening for aneuploidies in the first and second 
trimester is an important aspect of prenatal testing. The 
overall prevalence of aneuploidy is around 1 in 228 
(0.4%) - which includes live births, miscarriages and 
intra uterine fetal demise (IUFD). The three most 
common trisomies- Trisomy 21, 18 and 13 constitute 
71% of all aneuploidies. Trisomy 21 or Down’s 
syndrome is the commonest (53%). First trimester 
screening has proved effective in identifying aneuploid 
fetuses, the definitive diagnostic test for aneuploidy 
available in first trimester is chorion villous sampling 
(CVS).  
THIS ARTICLE AIMS TO 
1) Discuss the current methods of prenatal 
screening in the first trimester, 
2) Review the ultrasound, biochemical markers and 
newer methods- like non-invasive prenatal testing 
(NIPT), used in prenatal screening and  
3) Application of the information gained through 
these tests to our clinical practice. 
GUIDELINES FOR PRENATAL SCREENING 
The first method of screening for aneuploidies was 
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and the increased incidence of trisomy 21. This method 
of screening was introduced in the early 1970s, with 
the traditional recommendation of amniocentesis to all 
women above 35 years of age. In the 1970s about 5% 
of the pregnant population belonged to this group. 
However with advancing maternal age in most 
developed countries, this population has now increased 
to around 15 to 20%.  
In 2007, ACOG (American College of Obstetricians 
and Gynaecologists) opined that invasive testing like 
amniocentesis should be advised based on multiple 
screening test results and that advanced maternal age 
alone should not be the indication for invasive testing. 
They also suggested that screening should be offered 
to all pregnant women who attend the antenatal clinic 
prior to 20 weeks in order to determine the patient 
specific risk for chromosomal defects [1].  
Every woman has a risk of her fetus or baby having 
a chromosomal defect. The back ground or a priori risk 
depends on the maternal age and gestational age of 
the fetus. The patient specific risk is then calculated by 
multiplying this a priori risk with a series of likelihood 
ratios depending on the screen test results. Everytime 
a test is performed, the a priori risk is multiplied by the 
likelihood ratio of the test to calculate a new risk which 
then becomes the new risk for the next test. [2] 
Likelihood ratio is calculated as- percentage of 
chromosomally abnormal fetus/ % of normal fetus with 
a given test result or measurement. 
IMPORTANCE OF MATERNAL AGE AND PERIOD 
OF GESTATION 
The prevalence of trisomy 13, 18 and 21 increase 
with maternal age. However since these trisomies are 
associated with a high risk of miscarriage and 
intrauterine fetal demise, its prevalence decreases with 
increase in the period of gestation [3, 4]. e.g. the risk of 
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T21 in a woman aged 40 years, decreases from 1 in 51 
at first trimester to 1 in 113 at term. This is because the 
rate of spontaneous loss of T21 fetuses between 12 to 
40 weeks is about 30%. [5, 6] Similarly for T13 and T18 
the rate of miscarriage or fetal demise between 12 to 
40 weeks is about 80%. The prevalence of Turner’s 
syndrome (45, XO) is about 1 in 1500 at 12 weeks 
decreases to 1 in 3000 at 20weeks and 1 in 4000 at 
term. Turner’s syndrome is usually related to loss of 
paternal X chromosome and is thus unrelated to 
increased maternal age. For the sex chromosome 
aneuploidies- ( 47,XXY, 47,XYY and 47,XXX) there is 
no significant change with maternal age, and since the 
rate of fetal loss does not increase as the pregnancy 
progresses, its prevalence of 1 in 500 does not change 
with increase in the gestational age. Polyploidy is 
extremely lethal, reported in about 2% of recognised 
pregnancy, rarely seen as live birth, the prevalence at 
12weeks and 20 weeks is about 1 in 2000 and 1 in 
2,50,000 respectively [7]. 
PREVIOUS HISTORY OF AFFECTED PREGNANCY 
Maternal history of trisomy in a previous pregnancy 
increases the risk in the current pregnancy, for that 
trisomy by 0.75% higher than her a priori risk [8]. Thus 
for a woman of 35 years, who has had a previous baby 
with T21 , the risk at 12 weeks increases from 1 in 249 
(0.4%) to 1 in 87 i.e. (1.15%). Likewise for a woman 
aged 25 years, the risk for T21 increases from 1 in 946 
(0.106%) to 1 in 117 (0.856%). This increase in risk 
occurs because a small proportion of couples with a 
previous affected pregnancy suffer from parental 
mosaicism or abnormal dysjunction, the risk of 
recurrence in this group is high. However in a majority 
of couples (about 95%) the risk is not increased. 
PRENATAL SCREENING COMPONENTS IN THE 
FIRST TRIMESTER INCLUDE 
• First trimester ultrasound 
• First trimester biochemical markers 
• Non Invasive Prenatal Testing (NIPT)  
The advantages of screening early in pregnancy are 
many. It gives information about the pregnancy at an 
earlier date and definitive diagnostic test can be 
performed by chorion villous sampling (CVS), should 
there be a need for invasive diagnostic testing. 
Ultrasound can pick up most anomalies in the first 
trimester, it is also a good time to date the pregnancy 
and determine the chorionicity for twin gestations. Most 
pregnant women would prefer to know about the status 
of their pregnancy early rather than wait till the second 
trimester. [9] And finally termination based on 
diagnostic tests would be a lot safer at this point of time 
than later in pregnancy. 
NUCHAL TRANSLUCENCY 
In 1992, Nicolaides and co-workers described the 
sonographic appearance of fluid beneath the skin, at 
the back of the fetal neck, seen in all foetuses in the 
first trimester. They called this the nuchal translucency 
(NT) and reported an increased incidence of 
aneuploidies, specially trisomies in foetuses having an 
increased NT thickness [10, 11]. It is now well 
documented that an increased NT is associated with 
increased risk of aneuploidies and birth defects. The 
concept of measuring the NT in all foetuses in the first 
trimester forms the basis of first trimester screening by 
ultrasound. 
The Fetal Medicine Foundation has very strict 
criteria for measuring the nuchal translucency [11-15]. 
• The gestational age of the fetus should be 11 to 
13+6 weeks with a CRL between 45-84 mm 
• It should be a good mid- sagittal view with the 
fetus in neutral position 
• The magnification should be such that only the 
fetal head and thorax should be in the image 
• The maximum thickness of the subcutaneous 
translucency should be measured. Fetal skin 
should be distinguished from the amnion. 
• The cross bar of the calipers measuring the NT 
should merge with the white line of the border of 
the subcutaneous translucency 
More than one measurement must be taken and the 
largest recorded. In 5-10% of cases the umbilical cord 
may be around the neck, in such a situation the NT 
should be measured above and below the cord and an 
average of the two readings should be taken. 
The NT increases with the increase in the crown 
rump length (CRL) and gestational age. The median 
NT increases from 1.2mm at a CRL of 45mm to 1.9mm 
at a CRL of 84mm, likewise the 95
th
 centile increases 
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from 2.1mm to 2.7mm from a CRL of 45mm to 84mm 
[16]. A positive NT scan is defined as a NT 
measurement which is more than the 95
th
 centile for a 
given CRL. The larger the NT measurement, the higher 
the likelihood ratio and therefore greater the new risk, 
in contrast the smaller the NT, lower the new risk for 
chromosomal abnormality. The thickness of the NT is 
important in estimating the risk and not its appearance 
e.g. whether it is septated or not, restricted to the fetal 
neck or enveloping the entire fetus [17]. Increased NT 
usually resolves after 14 weeks, however in some 
cases it can further evolve to nuchal oedema, cystic 
hygroma or fetal hydrops. The median NT for normal 
foetuses is 2mm, and significantly higher for 
aneuploidies 3.5mm for T21, 5.5mm for T18, 4mm for 
T13 and 9.2mm for 45XO.  
Apart from chromosomal abnormalities a large 
number of other defects can result in an increased NT 
thickness such as- cardiac defects, genetic anaemias - 
thalasemia, congenital erythropoetic porphyria , 
fanconi’s syndrome, venous congestion in head and 
neck, obstruction of lymphatic drainage, altered 
composition of extracellular matrix, fetal 
hypoprotenemia and fetal infections like parvo virus 
B19. About 20% of foetuses with increased NT 
thickness are aneuploid. The rest 80% have no 
chromosomal abnormality, of them 2.5% die in utero, 
10% have major structural defects and 87.5% are 
normal. This suggests that NT is a marker and if the 
karyotype is normal and no other structural abnormality 
is detected, the long term outcome of foetuses with 
increased NT is not adverse [18-23]. 
MATERNAL SERUM BIOCHEMICAL MARKERS 
AND FIRST TRIMESTER SCREENING FOR 
ANEUPLODIES 
In the last 25 years several biochemical markers 
have been evaluated for screening purposes, the two 
most important and useful markers in the first trimester 
are- free beta HCG and pregnancy associated plasma 
protein A (PAPP- A). Maternal free beta HCG normally 
decreases beyond 10 weeks and PAPP-A increases till 
term. Levels of these two markers vary in aneuploid 
foetuses. Each type of aneuploidy has its own 
biochemical profile. (24-28) 
In T21, free  HCG tends to be higher and PAPP-A 
lower than euploid foetuses. In T13 and T18- both the 
markers are substantially lower, in sex chromosome 
aneuploidies PAPP-A alone tends to be lower. In 
triplody levels depend on the origin of the additional set 
of chromosome- The diandric type of triploidy is 
associated with very high levels of serum free  hCG 
and mildly decreased levels of PAPP-A. In digynic 
triploidy, both free  hCG and PAPP-A are significantly 
decreased [29-34]. 
Maternal weight, race, smoking and method of 
conception can affect the levels of these biochemical 
markers, also different laboratory assays yield different 
results. Therefore all these factors should be taken into 
account for risk analysis in any algorithm for prenatal 
screening. 
 
Figure 1: Measurement of NT. Nasal bone depicted by an arrow. 
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The first trimester combined screening, includes - 
maternal age, maternal history, gestational age, NT 
measurement, and maternal serum levels of free  
hCG and PAPP-A. For a false positive rate of 5% the 
detection rate for combined first trimester screening 
test is as high as 90% for all trisomies ( Trisomy 21, 18 
and 13) and for monosomy X [35, 36]. Structural 
anomalies usually seen in aneuploid foetuses can also 
be detected in first trimester ultrasonography. 
OTHER ULTRASOUND MARKERS USED IN 
SCREENING FOR ANEUPLOIDY 
Nasal Bone (NB) 
With the turn of the century in 2001 it was 
recognised that nasal bone is absent in 60-70% of 
foetuses with trisomy 21. The image of the nose has 
three distinct lines (Figure 1). The top line represents 
the nasal skin, the bottom one which is thicker and 
more echogenic than the overlying skin represents the 
nasal bone. The third line almost in continuity with the 
skin, but slightly at a higher level represents the tip of 
the nose. A normal nasal bone is more or as echogenic 
as the overlying skin. The nasal bone is absent in 60-
70% of T21 and 1-2.5% of euploid foetuses. Absence 
of NB in normal fetus is maximum in individuals of 
African ethnicity (10%). NB is absent in 30% and 50% 
of foetuses with T13 and T18 respectively [37-40]. 
Ductus Venosus 
The ductus venosus is an unique shunt in the fetus 
which directs almost 50% of the well oxygenated blood 
from the hepatic portion of the umbilical vein to the 
inferior vena cava. Abnormal flow in the ductus 
venosus in the first trimester is associated with 
chromosomal defects, cardiac anomalies and poor 
perinatal outcome. The blood flow in the ductus has a 
typical waveform. There is a high velocity flow during 
ventricular systole (S wave) and ventricular diastole (D 
wave) and a rapid drop in the forward flow during atrial 
contraction (a wave). However throughout the cardiac 
cycle it is a forward flow in the ductus venosus wave 
form in a normal fetus. Reversed ductus venosus a 
wave is seen more commonly in foetuses with 
aneuploid than euploid foetuse. (T21- 60%, T13 and 
T18- 53-58%, Monosomy- 75% as compared to 3% of 
normal foetuses) (Figure 2). The possible explaination 
for reversal of a wave could be- right ventricular 
dilatation with increased filling pressure and 
ultrastructural abnormalities in the heart resulting in 
ventricular wall stiffening. In these situations the right 
atrium would require a more forceful contraction to 
push the blood forward into the right ventricle across 
the tricuspid valve. This increase in atrial pressure gets 
transmitted to the ductus venosus, resulting in reversal 
of a waves [41-43]. 
 
Figure 2: Reversal of ‘a’ wave in ductus venosus. 
Tricuspid Regurgitation (TR) 
Tricuspid regurgitation is another important 
ultrasound marker in the first trimester and is more 
commonly seen in the aneuploid than in euploid 
foetuses (55% in T21, 33% in T18, 30% in T13, 38% in 
monosomy compared to 1% in normal foetuses) [44]. In 
aneuploid foetuses abnormalities are present in 
ultrastructural and biochemical levels, resulting in TR 
even in the absence of gross structural abnormality in 
the heart. e.g. in Trisomy 21 right ventricular dilatation 
result in an enlargement of the tricuspid valve annulus, 
which in turn results in TR [45]. 
The normal flow across the tricuspid valve during 
diastole is bi phasic - the first is due to increase in the 
forward flow in the beginning of the ventricular diastole 
and the second increase is due to atrial contraction. 
Any flow across the tricuspid valve during systole 
represents tricuspid regurgitation (TR) and is abnormal 
(Figure 3). The tricuspid regurgitant flow should last for 
at least 30% of the systole with the peak velocity of the 
regurgitant flow > 60 cm/sec.  
Frontomaxillary Facial Angle (FMF angle) 
A classical abnormal feature of trisomy 21 is a flat 
face and this can be objectively measured by 
measuring the FMF angle. Studies have demonstrated 
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that this angle decreases from 83.5° at a crown rump 
length (CRL) of 45mm to 76.4° at a CRL of 84mm [46]. 
FMF angle > 95
th
 centile for a given CRL is seen in 
almost 70% of foetuses with trisomy 21. 
Inclusion of the newer ultrasound markers in the 
screening protocols can improve the detection rate to 
95% for a false positive rate of 2.5% for T21 and 0.1% 
for T13 and T18 [43, 44, 47]. 
Thus there are several markers for screening a 
fetus in the first trimester, one approach could be to 
use all of them as the primary method of screening. 
However this might not always be practical as it 
requires high level of training, time and skill to perform 
all the ultrasound markers. Thus the Fetal Medicine 
Foundation has proposed an algorithm on how best to 
use the markers. The primary approach should begin 
with the first trimester combined screen test, which 
includes- maternal age and history, period of gestation, 
NT thickness , serum free hCG and PAPP-A. Based 
on the test results, the population is divided into three 
groups,-high risk (risk > 1 in 50 for trisomy 21) 
intermediate risk (risk 1 in 51 to 1 in 1000) and low risk- 
( risk < 1 in 1000). The high risk comprises of 1.5% of 
the population screened and has 85% of T21 fetuses. 
This group should be subjected to invasive prenatal 
diagnostic testing like CVS or the non-invasive prenatal 
testing (NIPT) to rule out aneuploidies. The 
intermediate risk group comprises of 15% of the 
population with 14% of T21, this group should be 
offered a second look ultrasound with the newer USG 
markers (Nasal Bone, Tricuspid valve, Ductus venosus 
and frontomaxillary facial angle). If the risk for trisomy 
is 1 in 100 or more after inclusion of the newer USG 
markers, NIPT or CVS should be offered. The rest are 
managed as in the low risk group. 83.5% of the 
screened population belong to the low risk group with 
about 1% of T21 foetuses. This group should be 
offered a routine mid trimester anomaly scan at 20 
weeks. 
First Trimester Screening in Multifetal Pregnancy 
First trimester screening in twin gestation includes 
maternal biochemical markers and USG, with similar 
detection and false positive rates as in singleton 
pregnancy [48, 49]. However the biochemistry in 
multiple pregnancy, does not perform as effectively, 
therefore USG is a very important marker for multiple 
pregnancy. It helps in determining the number of 
foetuses, chorionocity and any other structural 
abnormality in the fetus. 
The chorionicity is determined by the thickness of 
the amniotic membrane at the point it connects with the 
placenta- thicker Lambda sign for di-chorionic twins 
and thinner T sign for monochorionic twins. In 
monochorionic twins the risk is calculated based on the 
average of the NT measurement of both twins. In 
dichorionic twins, the risk is assigned to each fetus 
depending on the NT measurement of that fetus. 
Discordance in NT thickness in mono chorionic twins 
can be a predictor of early twin transfusion syndrome 
(TTTS) [50, 51]. Normal values of biochemical markers 
in di-chorionic twins is higher than mono chorionic 
twins. 
EFFICIENCY OF FIRST TRIMESTER SCREENING IN 
HIGHER ORDER MULTIPLE PREGNANCY IS LESS 
WELL UNDERSTOOD 
Fetal structural Abnormalities in First Trimester 
Most major structural abnormalities can now be 
detected by ultrasonography after 11 weeks of 
gestation. Several structural abnormalities are known 
 
Figure 3: Tricuspid regurgitation. 
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to be associated with aneuploidies- eg 
holoprosencephaly (risk 1:2 for T13), diaphragmatic 
hernia (risk 1:4 for T18), AVSD (risk 1:2 for T 21), 
omphalocele (risk 1:4 for T18, and 1:10 for T13) etc 
[52, 53]. All pregnancies detected with major structural 
abnormalities in the fetus should be subjected to 
invasive prenatal diagnostic testing- CVS, to rule out 
aneuploidy. 
Non Invasive Prenatal Testing (NIPT) 
NIPT utilizes cell free fetal DNA in maternal plasma 
as a screening tool for fetal aneuploidy. The genetic 
material is derived from dead placental tissue. About 
10% of cell free DNA in maternal circulation is of fetal 
origin – it has a short half life of about 20 minutes and 
disappears from the maternal circulation completely 
two hours post partum. This test can be performed 
anytime after 10 weeks. 
Quantitative differences in chromosome fragments 
in maternal blood is utilised to differentiate aneuploid 
fetuses (mainly trisomy 21,18,13 and some other 
aeuploidies like monosomy and sex chromosome 
aneuploidies) from normal fetuses. [54-59] Elevated 
levels of fetal genetic material for a particular 
chromosome, indicates trisomy of that chromosome. 
Test report can also interpret two sex chromosomes, 
with or without detection of Y chromosome.  
NIPT is not a diagnostic test; it can only screen for 
the common trisomies and has a high sensitivity and 
specificity- 98-99% and a false positive of < 1% for 
Trisomy 21 and 18. NIPT is indicated as a primary 
screen test in women who are at a high risk for 
aneuploidy and in those who have a positive first 
trimester combined screen test. However it can give no 
other genetic information about the pregnancy, or any 
other aspect of fetal wellbeing.  
The American College of Obstetricians and 
Gynaecologists (ACOG) and Society of Maternal and 
Fetal Medicine put forward a committee opinion in 2012 
on NIPT as follows [60]. 
NIPT is indicated in women with high risk for 
aneuploidy (advanced maternal age, prior affected 
pregnancy, positive first trimester screen test, parent 
carriers of Robertsonian translocation involving 
chromosome 13 and 21). 
It should not be a routine prenatal test and should 
not be offered to low risk and multifetal pregnancies.  
If fetal structural abnormality is detected in 
ultrasound, invasive diagnostic tests (CVS or 
amniocentesis) should be offered. 
A positive test should be referred for genetic 
counselling and offered CVS or amniocentesis for 
confirmation of test results.  
NIPT DOES NOT REPLACE THE DIAGNOSTIC 
ACCURACY OF CVS OR AMNIOCENTESIS 
Conclusion and Key points 
• Every woman has a risk that her fetus or baby 
has a chromosomal defect, hence screening 
should be offered to all pregnant women prior to 
20 weeks of gestation. 
• The back ground or a priori risk depends on the 
maternal age and period of gestation. 
• The basic first trimester combined screen test to 
calculate the risk include- maternal age, 
maternal history, gestational age, NT thickness, 
maternal serum levels of free hCG and PAPP-
A. 
• Additional ultrasound markers- nasal bone, TR, 
Ductus venosus flow and FMF angle can further 
improve the detection rates and is presently 
used for re-evaluating the risk in the population 
with intermediate risk. 
• Several structural abnormalities which are 
commonly associated with aneuploidies can be 
detected in the first trimester scan. 
• NIPT is an additional screening test available 
now for the common trisomies (T 21, 18 and 13) 
and is indicated in women who at a high risk for 
aneuploidy. 
• A positive combined screen test should be 
offered either NIPT or invasive diagnostic tests 
like chorion villous sampling (CVS) or 
amniocentesis. 
• NIPT is not a diagnostic test--a negative test 
result in NIPT does not completely rule out 
aneuploidy and a positive test result has to be 
confirmed by an invasive definitive diagnostic 
test- CVS or amniocentesis. 
The future of first trimester screening will largely 
depend upon where NIPT will figure in the algorithm for 
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first trimester screening. Will it accompany or replace 
the biochemical markers or NT screening? Will it also 
be advised to the low risk population and multifetal 
pregnancies? Presently ACOG does not recommend 
NIPT to these two groups as further research is 
required to sufficiently evaluate the use of NIPT in 
these groups. And finally whether NIPT as a 
technology will evolve further to enable detection of a 
larger number of aneuploidies, chromosomal 
mosiacism, microdeletions and duplications. 
All the standardised views and algorithm for 
screening mentioned in this article were developed by 
the Fetal Medicine Foundation, and can be accessed in 
their website- http//www.fetal medicine.com/training 
certification/11- 13+6 week scan. 
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